This producer of small heart pumps hasn’t missed a beat as the FDA approved Impella 2.5, a version of its flagship device for high-risk patients.
Looking for leads, investment insights, or competitive intelligence?Get Premium Access
Company Information
| Location | Danvers, MA |
| Industry | Medical Products & Equipment |
| Sector | Health Care |
| Fortune 500 Rank | - |
| Fortune 500 Profile | - |
| Current Streak | 1 |
| Years on List | 1 |
| CEO | Michael R. Minogue |
| Website | http://www.abiomed.com |
Revenue, Net Income
| Revenue Past Four Quarters | 230 |
| Net Income Past Four Quarters | 114 |
Growth Rates
| EPS 3 yr Annual Growth Rate | 65% |
| Rev 3 yr Annual Growth Rate | 20% |
| Total Return 3 yr Annual Rate | 42% |
| Beat S&P 3 yr Total Return? | yes |
Rank
| EPS Growth Rank | 34 |
| Revenue Growth Rank | 87 |
| Total Return Rank | 50 |
